Journal of applied physiology 88 , 14741480 (2000)
NAD(+) controls circadian reprogramming through PER2 nuclear translocation to counter aging
Kathy Zhou: Yeah, so I would say honestly, anyone with Type 2 I should have qualified that Type 2 to diabetes, which is where it's approved, would certainly probably benefit from this medication, even more so if you have something like, for example, fatty liver or cardiovascular risk or disease that's already there or kidney disease even with these medications potentially could be particularly helpful
Facing pressure from generics after semaglutides patent expired on March 20, 2026, Novo Nordisk cut prices by 36% effective April 1, 2026 bringing the 0.25 mg weekly shot down to 1,415 (about 5,660/month)